Home
Live Updates
Semaglutide 2.4 mg (Wegovy) Reduces Cardiovascular Risk in Overweight/Obesity with CVD : comparemela.com
Semaglutide 2.4 mg (Wegovy) Reduces Cardiovascular Risk in Overweight/Obesity with CVD
Full data from the SELECT trial offer insight into the 20% relative risk reduction associated with use of semaglutide 2.4 mg in patients with overweight or obesity and preexisting cardiovascular disease at AHA 2023.
Related Keywords
United States ,
American ,
Tiffanym Powell ,
Amit Khera ,
Campbellp Semaglutide Wegovy ,
Matt Kohlmann ,
Pa Michael Lincoff ,
American Heart Association ,
Novo Nordisk ,
National Institutes Of Health ,
Suzanne Tomsich Department Of Cardiovascular Medicine ,
University Of Texas Southwestern Medical Center ,
Vascular Thoracic Institute ,
American Heart Association Scientific Sessions ,
Cleveland Clinic ,
Suzanne Tomsich Department ,
Cardiovascular Medicine ,
Arnold Miller Family Heart ,
Thoracic Institute ,
Standard Deviation ,
Texas Southwestern Medical Center ,
National Institutes ,
Cardiovascular Outcomes ,
New England Journal ,
Accessed November ,
Cardiovascular Disease ,
comparemela.com © 2020. All Rights Reserved.